Pemphigus Vulgaris
Pemphigus vulgaris (PV) is caused by the production of autoantibodies against desmoglein proteins, which are essential for maintaining the integrity of cell-cell adhesion in the epidermis. As a leading provider of drug and therapeutic development services, we are committed to advancing the selection of pemphigus vulgaris therapeutic development solutions.
Overview of Pemphigus Vulgaris
Pemphigus vulgaris is a chronic autoimmune blistering disease that primarily affects the skin and mucous membranes. It is characterized by the presence of flaccid blisters and erosions that can occur anywhere on the body, including the scalp, face, trunk, and oral cavity. These blisters result from the loss of cell-cell adhesion due to autoantibodies targeting desmoglein 1 and desmoglein 3, key components of desmosomes. The disruption of desmosomes leads to the separation of keratinocytes, causing the formation of blisters and erosions.
Fig.1 Direct immunofluorescence detects IgG and/or C3 deposition on the surface of epidermal keratinocytes. (Didona D., et al., 2022)
Drug Discovery and Development for Pemphigus Vulgaris
Currently, the mainstay of PV therapeutic involves immunosuppressive therapies aimed at suppressing the autoimmune response. In cases of refractory or severe disease, monoclonal antibodies targeting B-cells, such as rituximab (RTX), have shown promising results. RTX induces B-cell depletion, thereby reducing autoantibody production. Other emerging therapies include intravenous immunoglobulin (IVIG), which provides passive immunomodulation, and immunoadsorption (IA), a therapeutic that removes pathogenic autoantibodies from circulation. To explore the range of therapeutic development solutions we offer, we encourage you to follow the provided links.
Small Molecule Drug
Probiotics Therapy
Therapeutic Antibody
Cell Therapy
Gene Therapy
Therapeutics Development
Our Services
Pemphigus vulgaris is a challenging autoimmune blistering disease that requires innovative drug and therapy development services. Our company is dedicated to advancing the field of PV therapeutic through our comprehensive diagnostics and therapy development services, expertise in animal models and in vitro model development, and preclinical research capabilities.
Active Disease Mouse Models
This model involves the adoptive transfer of Dsg3-deficient lymphocytes into immunodeficient mice that express Dsg3. This unique approach allows for the production of pathogenic anti-Dsg3 IgG antibodies, leading to the development of PV-like symptoms, including oral erosion and histological changes.
Active Disease Mouse Models
This model involves the adoptive transfer of Dsg3-deficient lymphocytes into immunodeficient mice that express Dsg3. This unique approach allows for the production of pathogenic anti-Dsg3 IgG antibodies, leading to the development of PV-like symptoms, including oral erosion and histological changes.
Rabbit Immune Models
Rabbits have been widely used in PV research due to their immunological similarities to humans and the ability to induce robust immune responses against Dsg antigens. By immunizing rabbits with Dsg antigens, we can elicit the production of pathogenic autoantibodies and observe the development of pemphigus-like skin lesions.
In Vitro Models
Our company provides a wide range of in vitro model development services that are specifically designed to support research on pemphigus vulgaris. These services encompass the development of cell-based models, including primary cultures of keratinocytes and immune cells, as well as cutting-edge organoid models.
Our company offers a wide range of preclinical research services, including pharmacokinetic and pharmacodynamic studies, drug safety assessments, and formulation development. In addition to the aforementioned range of services and models, we also specialize in tailoring customized solutions and developing disease models that precisely align with your distinctive requirements. Should our array of services capture your interest, we warmly encourage you to reach out to us without hesitation.
Reference
- Didona D., et al. "Pemphigus vulgaris: present and future therapeutic strategies." Dermatology Practical & Conceptual 12.1 (2022).